2 recruiting, 2 unknown, 1 active not recruiting, 1 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Chen Suning: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Chen Suning | 135 | 2024-12-25 | 2024-12-24 |
| RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. Blinatumomab Injection [Blincyto], Doxorubicin - ALL, Adult, Philadelphia-Negative ALL | Phase 2 | Recruiting | Chen Suning | 124 | 2024-02-05 | 2024-04-04 |
| The Impact of Donor COVID-19 Infection Status on the Recipient in Allo-HSCT COVID-19, Hematopoietic Stem Cell Transplantation | Unknown | Chen Suning | 40 | 2022-12-26 | 2023-01-12 | |
| A Study of Olverembatinib in the Treatment of Ph+ ALL Olverembatinib, Prednisone, Vincristine - Philadelphia-Positive ALL | Phase 2 | Unknown | Chen Suning | 55 | 2022-10-01 | 2022-09-01 |
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL Blinatumomab - B Acute Lymphoblastic Leukemia | Phase 2 | Completed | Chen Suning | 35 | 2022-09-08 | 2024-09-19 |
| Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML Venetoclax, Decitabine for Injection, Cytarabine - AML, Adult, Chemotherapy Effect | Phase 3 | Active not recruiting | Chen Suning | 188 | 2022-03-01 | 2024-10-03 |
Leukemia, Myeloid, Acute (2) · Burkitt Lymphoma (1) · COVID-19 (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
blinatumomab (2) · venetoclax (2) · Azacitidine (1) · Cytarabine (1) · Decitabine (1) · Doxorubicin (1) · Idarubicin (1) · Injections (1) · Prednisone (1) · Vincristine (1) · gilteritinib (1) · olverembatinib (1)
China (6)
Jing Lu, MD (1) · Suning Chen, PHD (1)